Pacifica Partners Inc. Sells 450 Shares of Colgate-Palmolive (NYSE:CL)

Pacifica Partners Inc. reduced its position in Colgate-Palmolive (NYSE:CL) by 1.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 36,894 shares of the company’s stock after selling 450 shares during the period. Colgate-Palmolive accounts for approximately 1.6% of Pacifica Partners Inc.’s portfolio, making the stock its 22nd largest holding. Pacifica Partners Inc.’s holdings in Colgate-Palmolive were worth $3,830,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Main Street Research LLC raised its stake in Colgate-Palmolive by 1.5% in the 2nd quarter. Main Street Research LLC now owns 6,939 shares of the company’s stock valued at $673,000 after acquiring an additional 100 shares during the period. Advisor OS LLC increased its position in shares of Colgate-Palmolive by 4.5% during the second quarter. Advisor OS LLC now owns 2,348 shares of the company’s stock valued at $228,000 after buying an additional 101 shares during the period. BLB&B Advisors LLC raised its stake in Colgate-Palmolive by 2.5% in the second quarter. BLB&B Advisors LLC now owns 4,337 shares of the company’s stock valued at $421,000 after purchasing an additional 104 shares in the last quarter. ZWJ Investment Counsel Inc. raised its stake in Colgate-Palmolive by 3.1% in the second quarter. ZWJ Investment Counsel Inc. now owns 3,591 shares of the company’s stock valued at $349,000 after purchasing an additional 109 shares in the last quarter. Finally, Hexagon Capital Partners LLC raised its stake in Colgate-Palmolive by 9.5% in the second quarter. Hexagon Capital Partners LLC now owns 1,274 shares of the company’s stock valued at $124,000 after purchasing an additional 110 shares in the last quarter. 80.41% of the stock is currently owned by institutional investors.

Colgate-Palmolive Stock Performance

NYSE:CL opened at $98.57 on Tuesday. The stock has a market cap of $80.87 billion, a P/E ratio of 31.19, a price-to-earnings-growth ratio of 3.62 and a beta of 0.40. The firm’s fifty day simple moving average is $103.65 and its 200 day simple moving average is $96.87. Colgate-Palmolive has a twelve month low of $68.44 and a twelve month high of $109.30. The company has a quick ratio of 0.70, a current ratio of 1.06 and a debt-to-equity ratio of 16.90.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, July 26th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.87 by $0.04. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $5 billion. Colgate-Palmolive had a net margin of 14.21% and a return on equity of 470.19%. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.77 earnings per share. As a group, research analysts predict that Colgate-Palmolive will post 3.57 EPS for the current year.

Colgate-Palmolive Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Friday, October 18th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.03%. The ex-dividend date is Friday, October 18th. Colgate-Palmolive’s dividend payout ratio is currently 63.29%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group raised their target price on shares of Colgate-Palmolive from $119.00 to $122.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. HSBC reaffirmed a “hold” rating on shares of Colgate-Palmolive in a research note on Friday, July 26th. Sanford C. Bernstein raised their target price on shares of Colgate-Palmolive from $100.00 to $103.00 and gave the company a “market perform” rating in a research note on Tuesday, July 30th. Wells Fargo & Company downgraded shares of Colgate-Palmolive from an “equal weight” rating to an “underweight” rating and set a $100.00 target price on the stock. in a research note on Monday, September 16th. Finally, Morgan Stanley increased their price target on shares of Colgate-Palmolive from $103.00 to $111.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.74.

Insider Buying and Selling at Colgate-Palmolive

In other Colgate-Palmolive news, Director Martina Hundmejean sold 2,313 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $103.86, for a total transaction of $240,228.18. Following the completion of the transaction, the director now owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Colgate-Palmolive news, insider Panagiotis Tsourapas sold 14,794 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $102.94, for a total transaction of $1,522,894.36. Following the completion of the transaction, the insider now owns 5,146 shares of the company’s stock, valued at approximately $529,729.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Martina Hundmejean sold 2,313 shares of Colgate-Palmolive stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $103.86, for a total value of $240,228.18. Following the completion of the transaction, the director now directly owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,490 shares of company stock valued at $4,486,063. 0.34% of the stock is currently owned by company insiders.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.